Cardio Diagnostics Publishes Novel and Scalable Pathways to Enhance Global Coronary Heart Disease Care through Precision Epigenetics in Epigenomics
September 20 2023 - 9:01AM
Business Wire
Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), a pioneer of
artificial intelligence-driven precision cardiovascular medicine
tests, today announced that researchers from Cardio Diagnostics and
Dr. Damon Broyles published a peer-reviewed article outlining
scalable pathways that leverage precision epigenetics to
revolutionize coronary heart disease (CHD) care globally, a leading
cause of death worldwide in the journal Epigenomics.
This review lays out an affordable, scalable framework to use
artificial intelligence-guided epigenetic assessments for CHD risk
assessment, diagnosis, and management. The digital PCR-based
approach requires only minimal infrastructure investments while
providing unparalleled personalized biological insights into the
drivers of each patient's CHD presentation.
According to the manuscript published online on September 13th,
current diagnostic methods like angiograms and exercise ECGs have
significant limitations with respect to sensitivity, scalability,
and assessment-related morbidity. These difficulties increase the
real-world cost of these tests and hinder the use of these tests in
developing economies or rural areas.
In response to these challenges, the Broyles’ led review
describes a potentially disruptive blood-based DNA test,
PrecisionCHD™. This test uses easily performed digital PCR
laboratory assays to quantify epigenetic signatures that are
interpreted by artificial intelligence (AI) to determine the
presence or absence of CHD. Though it required years of
development, the PrecisionCHD™ test can now be performed within
hours using standard laboratory equipment.
"Without a doubt, the future in precision epigenetics for
diagnosing and managing CHD is bright. We stand on the cusp of a
transformative era, with the potential to bring high-quality CHD
care to all corners of the globe,” noted lead author Damon Broyles,
MD, the VP of Clinical Innovation, Medical Director of Precision
Medicine and Vice Chair of Mercy Board of Research.
"Our research shows a clear pathway for precision epigenetics to
fill critical unmet needs in cardiac care on a national and global
scale," said Dr. Robert Philibert, Chief Medical Officer and
Co-Founder of Cardio Diagnostics. "Combining next-generation
epigenomics and AI enables earlier CHD detection, improved risk
stratification, and optimized treatment selection for patients
without risk from radiation or contrast dye-induced kidney damage,”
shared Dr. Philibert. “Furthermore, because the signatures are
dynamic, periodic retesting of key sites may allow clinicians to
determine the effectiveness of therapy and help usher in a new era
of Precision Epigenetics approaches for managing cardiovascular
care,” he added.
About Cardio Diagnostics
Cardio Diagnostics is an artificial intelligence-powered
precision cardiovascular medicine company that makes cardiovascular
disease prevention, detection, and management more accessible,
personalized, and precise. The Company was formed to further
develop and commercialize clinical tests by leveraging a
proprietary Artificial Intelligence (AI)-driven Integrated
Genetic-Epigenetic Engine (“Core Technology”) for cardiovascular
disease to become one of the leading medical technology companies
for improving prevention, detection, and treatment of
cardiovascular disease. For more information, please visit
www.cardiodiagnosticsinc.com.
Forward-Looking Statements
Certain statements and information included in this press
release constitute "forward-looking statements" within the meaning
of the Private Securities Litigation Act of 1995. When used in this
press release, the words or phrases “will”, "will likely result,"
"expected to," "will continue," "anticipated," "estimate,"
"projected," "intend," “goal,” or similar expressions are intended
to identify "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Such statements
are subject to certain risks, known and unknown, and uncertainties,
many of which are beyond the control of the Company. Such
uncertainties and risks include but are not limited to, our ability
to successfully execute our growth strategy, changes in laws or
regulations, economic conditions, dependence on management,
dilution to stockholders, lack of capital, the effects of rapid
growth upon the Company and the ability of management to
effectively respond to the growth and demand for products and
services of the Company, newly developing technologies, the
Company’s ability to compete, regulatory matters, protection of
technology, the effects of competition and the ability of the
Company to obtain future financing. An extensive list of factors
that can affect future results are discussed in the Current Report
on Form 10-K for the period ended December 31, 2022 and Form 10-Q
for the period ended June 30, 2023 under the heading “Risk Factors”
in Part I, Item IA thereof, and other documents filed from time to
time with the Securities and Exchange Commission. Such factors
could materially adversely affect the Company's financial
performance and could cause the Company's actual results for future
periods to differ materially from any opinions or statements
expressed within this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230920184442/en/
Investors: Gene Mannheimer Investor Relations 855-226-9991
investors@cardiodiagnosticsinc.com Media & Public Relations:
Khullani Abdullahi pr@cardiodiagnosticsinc.com
Cardio Diagnostics (NASDAQ:CDIO)
Historical Stock Chart
From Apr 2024 to May 2024
Cardio Diagnostics (NASDAQ:CDIO)
Historical Stock Chart
From May 2023 to May 2024